Skip to main content

Table 3 Detailed results of subgroup analyses for prognostic and predictive significance

From: Relationship between circulating tumor cells and tumor response in colorectal cancer patients treated with chemotherapy: a meta-analysis

  Sample time Method CellSearch
  Any Baseline During-chemotherapy CellSearch No-Cellsearch Baseline During- chemotherapy
Response rate(RRi) ¶ii 1.740[0.878-3.447], I 2 = 75.4% 1.258[0.990-1.598], I 2 = 6.9%;Fixed:1.263 [1.008-1.584],I 2 = 6.9% 2.315[1.242-4.316], I 2 = 0% 1.326[0.904-1.946],I 2 = 22.5% 5.2174 [2.3258-11.7041], N = 1iii 1.258[0.990-1.598], I 2 = 6.9%;Fixed:1.263 [1.008-1.584],I 2 = 6.9% 2.315[1.242-4.316],I 2 = 0%
Disease control rate(RR) Ψiv 1.354[1.002-1.830], I 2 = 80.8% 1.375[0.961-1.967], I 2 = 77.4% 1.535[1.170-2.016],I 2 = 69.8% 1.110[0.784-1.571],I 2 = 74.6% 2.005[1.052-3.821], I 2 = 87.7% 0.974[0.933-1.016], I 2 = 0.0% 1.451[1.116-1.887],I 2 = 36.3%
Disease control rate(RR) ¶ 1.354[1.065-1.721], I2 = 59.5% 1.248[0.874-1.783], I 2 = 74.7% 1.331[1.099-1.612], I 2 = 35.9% 1.292[1.005-1.660], I 2 = 42.4% 1.933[0.633-5.902],I 2 = 86.0% 0.974[0.933-1.016], I 2 = 0.0% 1.451[1.116-1.887],I 2 = 36.3%
CTCs change
Disease control rate (ORv: increase VS decrease) Ψ 27.088[4.960- 147.919], I 2 = 0.0% / / 39.000[2.932- 518.841], N = 1 20.570[2.170-194.950], N = 1 / /
HRvi for PFSvii(L/H to H VS H to Lviii) ¶ 2.095[1.105-3.969], I 2 = 74% / / 2.095[1.105-3.969], I 2 = 74% / / /
HR for OS(L/H to H VS H to L) ¶ 3.604[2.096-6.197], I 2 = 52.9% / / 3.604[2.096-6.197], I 2 = 52.9% / / /
Prognosis
HR for PFS Ψ 2.500[1.746-3.580], I 2 = 90.0%; Without Matsusaka 2.654[2.069-3.405], I 2 = 58.1% 1.853[1.405-2.445], I 2 = 83.6%; Without Matsusaka 1.942[1.549-2.435], I 2 = 47.6% 2.386[1.454-3.917],I 2 = 93.3%; Without Matsusaka 2.694[2.085-3.481], I 2 = 35.1% 1.769[1.180-2.651],I 2 = 90.2%; Without Matsusaka 2.059[1.563-2.712], I 2 = 50.4% 3.387[2.479-4.628],I 2 = 32.7% 1.422[1.102-1.835], I 2 = 82.5%; Without Matsusaka 1.578[1.355-1.837], I 2 = 0% 2.127[1.190-3.802], I 2 = 95%;
Without Matsusaka 2.697[2.208-3.294], I 2 = 0%
HR for PFS 2.237[1.485-3.370], I 2 = 91.8%; Without Matsusaka 2.476[1.830-3.350], I 2 = 68.0% 1.621[1.224-2.146], I 2 = 83.6% Without Matsusaka 1.736[1.383-2.180], I 2 = 44.5% 2.100[1.273-3.465],I 2 = 93.7%; Without Matsusaka 2.593[2.152-3.124], I 2 = 0.0% 1.769[1.180-2.651],I 2 = 90.2%; Without Matsusaka 2.059[1.563-2.712], I 2 = 50.4% 3.618[1.976-6.624],I 2 = 65.8% 1.422[1.102-1.835], I 2 = 82.5%; Without Matsusaka 1.578[1.355-1.837], I 2 = 0% 2.127[1.190-3.802], I 2 = 95%;
Without Matsusaka 2.697[2.208-3.294], I 2 = 0%
Operation: HR for PFS¶ 3.433[2.111-5.583],I 2 = 72.8% 2.377[1.692-3.339], I 2 = 18.8% 3.344[1.135-9.852], I 2 = 75.6% 1.981[1.478-2.654], N = 1 4.265[3.079-5.907],I 2 = 0.0% 1.943[1.362-2.770], N = 1 2.063[1.231-3.458], N = 1
HR for OSix 2.856[1.959-4.164],I 2 = 83.4%; Without Matsusaka 3.139[2.167-4.545],I 2 = 76.1% 2.356[1.957-2.836], I 2 = 14.0%; Without Matsusaka 2.288[1.941-2.697], I 2 = 1.7% 3.292[1.611-6.726],I 2 = 96.2%; Without Matsusaka 3.998[2.478-6.449], I 2 = 79.5% 2.452[1.484-4.050],I 2 = 89.9%; Without Matsusaka 2.895[1.697-4.940], I 2 = 85.9% 3.367[1.882-6.023],I 2 = 68.6% 2.310[1.759-3.035], I 2 = 49.9%; Without Matsusaka 2.210[1.716-2.846], I 2 = 46.8% 2.802[1.175-6.684],I 2 = 97.4%; Without Matsusaka 3.792[2.052-7.009],I 2 = 86.5%
HR for OS¶ 2.642[1.716-4.067],I 2 = 86.2%; Without Matsusaka 2.968[1.913-4.606],I 2 = 80.4% 2.373[1.873-3.006], I 2 = 34.3%; Without Matsusaka 2.284[1.836-2.842], I 2 = 27.6% 2.787[1.321-5.882],I 2 = 96.6%; Without Matsusaka 3.536[2.149-5.818],I 2 = 81.8% 2.452[1.484-4.050], I 2 = 89.9%; Without Matsusaka 2.895[1.697-4.940],I 2 = 85.9% 2.969[1.053-8.375],I 2 = 78.2% 2.310[1.759-3.035], I 2 = 49.9%; Without Matsusaka 2.210[1.716-2.846], I 2 = 46.8% 2.802[1.175-6.684],I 2 = 97.4%; Without Matsusaka 3.792[2.052-7.009],I 2 = 86.5%
Operation: HR for OS¶ 3.681[1.833-7.394],I 2 = 81.8% 1.890[1.407-2.539], I 2 = 0.0% 4.069[0.872-18.980],I 2 = 87.0% 1.738[1.296-2.332], N = 1 4.678[2.267-9.654],I 2 = 67.5% 1.642[1.149-2.345], N = 1 1.961[1.168-3.295], N = 1
  1. i.RR: relative risk.
  2. ii¶: included patients with metastatic colorectal cancer.
  3. iiiN = 1: only one eligible study without pooled analysis.
  4. ivΨ: included patients with metastatic and II–IV stages colorectal cancer.
  5. vOR: odds ratio.
  6. viHR: hazard ratio.
  7. viiPFS: progression-free survival.
  8. viiiH: high CTCs level; L: low CTCs level.
  9. ixOS: overall survival.